Stockscreener 앱 받기
92.08
1.46%
-1.30
Revvity Inc 주식(RVTY)의 최신 뉴스
Revvity to Hold Earnings Call on Monday, October 27, 2025 - PharmiWeb.com
Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout - MedTech Dive
Is Revvity Inc. stock undervalued vs historical averagesBuy Signal & Community Verified Trade Alerts - newser.com
Is Revvity Inc. stock a top pick for value investorsMarket Growth Report & Fast Momentum Entry Tips - newser.com
How Revvity Inc. (PKN) stock reacts to Fed tightening2025 Key Highlights & Weekly High Return Opportunities - newser.com
Revvity Inc. stock trend outlook and recovery pathBreakout Watch & Comprehensive Market Scan Reports - newser.com
What drives Revvity Inc stock priceShort-Term Trading Alerts & These Picks Are Just One Breakout Away - earlytimes.in
Can a trend reversal in Revvity Inc. lead to recoveryChart Signals & Stock Timing and Entry Methods - newser.com
Using AI based signals to follow Revvity Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com
Chart based analysis of Revvity Inc. trends2025 Price Targets & Long-Term Investment Growth Plans - newser.com
Revvity to develop type 1 diabetes early detection assay with Sanofi - Investing.com Nigeria
Automated trading signals detected on Revvity Inc.Trade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Order flow analysis tools used on Revvity Inc.July 2025 WrapUp & Weekly Setup with ROI Potential - newser.com
Will Revvity Inc. (PKN) stock enhance shareholder valueDay Trade & Expert Approved Trade Ideas - newser.com
Lucem, Revvity partner with Sanofi for early T1D detection - BioWorld MedTech
Barclays Adjusts Revvity (RVTY) Price Target, Maintains Overweig - GuruFocus
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes - PharmiWeb.com
Barclays Maintains Revvity (RVTY) Overweight Recommendation - Nasdaq
Revvity Expands Type 1 Diabetes Program With Sanofi Support - Nasdaq
Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay - GuruFocus
Revvity Launches Program to Expand Type 1 Diabetes Diagnosis Offering - MarketScreener
Barclays Adjusts Price Target on Revvity to $100 From $110, Maintains Overweight Rating - MarketScreener
Barclays Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $100 - 富途牛牛
Will Revvity Inc. stock sustain high P E ratiosJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
Bruker, Agilent, Revvity, Avantor, and Bio-Techne Shares Are Soaring, What You Need To Know - The Globe and Mail
Revvity Launches AI Software Transforming Preclinical Imaging - Precedence Research
How to recover losses in Revvity Inc. stockRate Cut & High Conviction Buy Zone Alerts - newser.com
Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis - MarketScreener
Revvity (RVTY) Unveils Advanced AI Imaging Software for Researchers - GuruFocus
Revvity launches AI-powered multimodal analysis software for imaging research By Investing.com - Investing.com South Africa
Revvity launches AI-powered multimodal analysis software for imaging research - Investing.com
Revvity, Inc. Unveils New AI Software Offering to Transform Preclinical Imaging Analysis - MarketScreener
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Yahoo Finance
Revvity Inc PKN Stock Analysis and ForecastMarket Sentiment Shifts & Affordable Portfolio Trading - earlytimes.in
Is Revvity Inc PKN a good long term investmentDouble Top/Bottom Patterns & High Return Portfolio Growth - earlytimes.in
What analysts say about Revvity Inc stockGlobal Trade Effects & Affordable Trading Strategies - earlytimes.in
Published on: 2025-09-27 18:11:56 - newser.com
1.72%
2.69%
자본화:
|
볼륨(24시간):